Evidence map›Paper›PMID 33678311›Full record

ReviewSeminars in nephrology2020

Uric Acid and Urate in Urolithiasis: The Innocent Bystander, Instigator, and Perpetrator.

Emmanuel Adomako, Orson W Moe

Open access · greenAbstract readReview
In one paragraph

Review in Seminars in nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Epidemiology of Kidney Stones.Healthcare (Basel, Switzerland) · 2023
    Review
  19. Article
  20. Uric Acid in Parkinson's Disease: What Is the Connection?Movement disorders : official journal of the Movement Disorder Society · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Emmanuel AdomakoDepartment of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX.
Orson W MoeDepartment of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Physiology, University of Texas Southwestern Medical Center, Dallas, TX; Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: orson.moe@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · US

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
RENAL BASIS OF HYPOCITRATURIAP01DK020543 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HUANG, CHOU-LONG · 1986 to 2008
$12.7M
Pathogenesis of Uric Acid Nephrolithiasis: The Multifaceted Role of Renal LipidsR01DK081423 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MAALOUF, NAIM M, MOE, ORSON W · 2009 to 2023
$6.1M
RENAL CONTROL OF BODY COMPOSITION AND BLOOD PRESSURET32DK007257 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BAUM, MICHEL GERARD, MOE, ORSON W · 1986 to 2021
$5.0M
Klotho: Therapeutic Agent for Ischemia Reperfusion Induced Acute Kidney InjuryR01DK092461 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HU, MING-CHANG · 2011 to 2021
$3.7M
Klotho and Phosphate in Chronic Kidney Disease: Pathogenesis and TherapeuticsR01DK091392 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HU, MING-CHANG, MOE, ORSON W · 2011 to 2021
$3.2M
Origin of Excess Acid in Uric Acid UrolithiasisR01DK115703 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BROWNING, JEFFREY D, MOE, ORSON W · 2019 to 2023
$2.2M
Association of baseline and time-varying serum magnesium levels with cardiovascular disease events in SPRINT participants with and without chronic kidney diseaseR21HL145424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2019 to 2020
$257k
NHLBI NIH HHS R21 HL145424NIDDK NIH HHS P01 DK020543NIDDK NIH HHS P30 DK079328NIDDK NIH HHS R01 DK081423NIDDK NIH HHS R01 DK091392NIDDK NIH HHS R01 DK092461NIDDK NIH HHS R01 DK115703NIDDK NIH HHS T32 DK007257
6 · The paper itself

Abstract

Uric acid is an end product of purine metabolism in human beings. An unusual and still unexplained phenomenon is that higher primates have relatively high uric acid levels in body fluids owing to a combination of absence of degradation and renal retention. The physiologic purpose of high uric acid levels still is enigmatic, but the pathobiologic burden is a variety of crystallopathies owing to the low aqueous solubility of uric acid such as gouty arthritis and acute uric acid nephropathy. In the urinary space, three distinct conditions result from chronic uric acid and/or urate precipitation. The first and most common variety is uric acid urolithiasis. In this condition, urate is a victim of a systemic metabolic disease in which increased acid load to the kidney is coupled with diminished urinary buffer capacity owing to defective ammonium excretion, resulting in titration of urate to its sparingly soluble protonated counterpart, uric acid, and the formation of stones. Uric acid is the innocent bystander of the crime. The second variety is hyperuricosuric calcium urolithiasis, in which uric acid confers lithogenicity via promotion of calcium oxalate precipitation by multiple mechanisms involving soluble, colloidal, and crystalline urate salts. Uric acid is the instigator of the crime. The third and least common condition involves urate as an integral part of the urolith as an ammonium salt driven by high ammonium and high urate concentrations in urine. Here, uric acid is one of the perpetrators of the crime. Both known and postulated pathogenesis of these three types of urolithiasis are reviewed and summarized.

Indexed as

Kidney DiseasesUrinary CalculiUrolithiasisAnimalsCalcium OxalateHumansUric AcidCalcium OxalateUric Acidammonium uratecalciumhyperuricosuricKidney stonesuric acid urolithiasis

Identifiers

PMID33678311
PMCPMC8127876
OpenAlexW3134772030

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.